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Proteasomes degrade most proteins in mammalian
cells and are established targets of anticancer drugs.
All eukaryotic proteasomes have three types of
active sites: chymotrypsin-like, trypsin-like, and
caspase-like. Chymotrypsin-like sites are the most
important in protein degradation and are the primary
target of most proteasome inhibitors. The biological
roles of trypsin-like and caspase-like sites and their
potential as cotargets of antineoplastic agents are
not well defined. Here we describe the development
of site-specific inhibitors and active-site probes of
chymotrypsin-like and caspase-like sites. Using
these compounds, we show that cytotoxicity of
proteasome inhibitors does not correlate with inhibi-
tion of chymotrypsin-like sites and that coinhibition
of either trypsin-like and/or caspase-like sites is
needed to achieve maximal cytotoxicity. Thus, cas-
pase-like and trypsin-like sites must be considered
as cotargets of anticancer drugs.INTRODUCTION
The ubiquitin-proteasome pathway is essential in the mainte-
nance of protein homeostasis in all eukaryotic cells; it is involved
in the regulation of numerous biological processes, such as the
cell cycle, immune surveillance, inflammatory response, metab-
olism, circadian rhythms, and others; and in the development of
many diseases. Proteasome inhibition causes apoptosis of
malignant cells (Adams, 2004; Kisselev and Goldberg, 2001).
The proteasome inhibitor bortezomib (Velcade, PS-341) is used
for the treatment of multiplemyeloma andmantle cell lymphoma.1278 Chemistry & Biology 16, 1278–1289, December 24, 2009 ª2009Three other proteasome inhibitors are at different stages clinical
trials (Chauhan et al., 2005; Demo et al., 2007; Piva et al., 2008).
The 26S proteasome is a large (1.6–2.4 MDa), hollow cylin-
drical, multifunctional particle that consists of a 20S proteolytic
core and one or two 19S regulatory complexes. Each eukaryotic
20S core particle has three pairs of proteolytic sites with distinct
substrate specificities (Arendt and Hochstrasser, 1997; Chen
and Hochstrasser, 1996; Dick et al., 1998; Groll et al., 1997;
Heinemeyer et al., 1997). The b5 proteolytic sites are ‘‘chymo-
trypsin-like’’ (Chym-L). The b2 sites are ‘‘trypsin-like’’ (Tr-L).
The b1 sites cleave after acidic residues (Glu, Asp) and are
referred to as ‘‘postacidic,’’ PGPH (‘‘post-glutamate peptide
hydrolase’’), or ‘‘caspase-like’’ (Casp-L).
Tissues of the immune system also express immunoprotea-
somes, in which b5, b1, and b2 catalytic subunits are replaced
by their major histocompatibility complex (MHC)-locus-encoded
counterparts, LMP7 (b5i), LMP2 (b1i), and MECL (b2i). Immuno-
proteasomes have higher Chym-L and Tr-L activities and much
lower Casp-L activity, presumably allowing them to generate
more peptides for utilization in MHC class I antigen presentation
(Cascio et al., 2001).
The biological role of b1, b2, and b5 active sites was first ad-
dressed by site-directed mutagenesis of catalytic threonines in
the yeast S. cerevisiae. Inactivation of Chym-L (b5) sites caused
significant retardation of growth, increase in stress sensitivity,
and accumulation of proteasome substrates (Chen and
Hochstrasser, 1996; Heinemeyer et al., 1997). Inactivation of
Casp-L (b1) sites caused no phenotypic or proteolytic defects
(Arendt and Hochstrasser, 1997; Heinemeyer et al., 1997). Inac-
tivation of Tr-L (b2) sites reduced growth rates slightly and
reduced the degradation rate of some model substrates (Arendt
and Hochstrasser, 1997; Heinemeyer et al., 1997). A strain in
which both b1 and b2 sites were inactive had a stronger growth
defect than strains in which only the b2 sites were inactivated,
but had fewer phenotypic defects than the strain lackingElsevier Ltd All rights reserved
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Figure 1. Characterization of the Novel
b5-Specific Proteasome Inhibitor NC-005
(A) Structures of YU-101 and NC-005.
(B and C) RPMI-8226 cells were treated with YU-
101 and NC-005 for 1 hr and proteasome activity
was measured in cells with ProteasomeGlo assay.
Mock-treated cells served as control. Values are
averages and standard error (± SE) of two experi-
ments.
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Site-Specific Proteasome Inhibitorsfunctional b5 sites (Heinemeyer et al., 1997). It should be noted
that these mutations also caused defects in the proteasome
assembly (Groll et al., 1999) and that some of these phenotypes
may have been caused by assembly defects. To distinguish
between biological effects caused by inhibition of assembly
and inhibition of proteolysis, as well as to study the biological
roles of proteasome active sites in mammalian cells, specific
inhibitors of active sites are needed.
Because these results from yeast studies showed that Chym-L
sites are the most important sites in protein breakdown by the
proteasome and because of the ability of hydrophobic peptides
to enter cells, various synthetic proteasome inhibitors were opti-
mized to block the b5 sites, which cleave after hydrophobic resi-
dues (Kisselev and Goldberg, 2001). Less attention has been
paid to the ability of these substances to block the b1 or b2 sites
(Kisselev andGoldberg, 2001). Bortezomib was developed as an
inhibitor of Chym-L (b5 and b5i) sites (Adams et al., 1999). Only
after approval of this agent by the FDA was it discovered that it
also inhibits Casp-L (b1 and b1i) sites and Tr-L (b2i) sites in the
immunoproteasomes (Altun et al., 2005; Berkers et al., 2005;
Kisselev et al., 2006). Similarly, salinosporamide A (NPI-0052)
inhibits Chym-L, Tr-L, and, to some extent, Casp-L sites. This
agent has a more potent antineoplastic activity in mice than bor-
tezomib (Chauhan et al., 2005), further suggesting that coinhibi-
tion of Tr-L and Casp-L sites might be important for the antineo-
plastic activity of proteasome inhibitors. This idea is further
supported by two studies in the literature that report that selec-
tive inhibition of b5 sites caused moderate inhibition of degrada-
tion of model substrates by purified proteasomes and little or no
inhibition of protein breakdown inside cells. Significant (more
than 50%) inhibition of protein degradation is achieved only
when both b5 and either b1 or b2 sites are inhibited (Kisselev
et al., 2006; Oberdorf et al., 2001). Thus, b1 and b2 sites play
an important role in protein degradation, suggesting that they
should be considered as cotargets of anticancer drugs.
In this study, we report the development of two novel specific
inhibitors of Chym-L and Casp-L sites. Using these compounds,
we demonstrate that cytotoxicity of proteasome inhibitors rarely
correlates with inhibition of Chym-L (b5) sites alone and that
coinhibition of either b1 or b2 sites is required for b5-specific
inhibitors to achieve maximal cytotoxicity.Chemistry & Biology 16, 1278–1289, December 24, 2009 ªRESULTS
Novel-Specific Inhibitor
of Chymotrypsin-like Sites
The simplest way to test whether inhibi-
tion of b5 sites is sufficient to inhibit cell
growth and cause cell death would beto examine the effects of a highly specific inhibitor of these
sites on cell growth and viability. For the purpose of this study,
‘‘highly specific’’ would mean that inhibitor does not cause a
significant decrease—i.e., more than 20%—in the activity of
Casp-L and Tr-L sites under conditions where Chym-L sites
are inhibited by at least 95%. We initially intended to use
YU-101 (Figure 1A), developed as specific inhibitor of Chym-L
sites (Elofsson et al., 1999), but discovered that it inhibits Tr-L
and Casp-L sites before complete inhibition of Chym-L sites
can be achieved (Figure 1B). Hence, we decided to develop
a more specific inhibitor.
YU-101 is a tetrapeptide epoxyketone (Figure 1A). Contrary to
other major groups of proteasome inhibitors, such as peptide
vinyl sulfones, peptide boronates, b-lactones, and peptide alde-
hydes, which can react with either cysteine or serine proteases
or both, epoxyketones are exquisitely proteasome specific
(Groll and Huber, 2004; Kisselev and Goldberg, 2001). One
compound of this class, the YU-101 derivative carfilzomib
(Demo et al., 2007), is in stage II clinical trials. We have therefore
focused our development of site-specific inhibitors on the epoxy-
ketone pharmacophore, varying the peptide portion of the drug
to optimize compound specificity.
In reviewing the literature, we noticed that peptide aldehyde
1-naptylacetyl(Nac)-4-methyl-tyrosine(mTyr)-phenylalanine-4-
methyl-tyrosinal was exceptional in that it did not inhibit Casp-L
and Tr-L sites (Momose et al., 2005). We have synthesized an
epoxyketone derivative of this compound, Nac-mTyr-Phe-
Leu-ek (Figure 1A), electing to use Leu in the P1 position for
simplicity of synthesis and better cell permeability. We have
designated this compound NC-005, where NC stands for Norris
Cotton Cancer Center and 5 emphasizes the fact that it inhibits
b5 and b5i subunits. We also decided that for naming all future
compounds of this type prepared in our laboratory, the last digit
would match the active site inhibited. Using this terminology,
the second inhibitor of b5 sites would be NC-015, the first
inhibitor of b2 sites NC-002, and the first inhibitor of b1 sites
NC-001.
As expected, NC-005 was more specific than YU-101 while
maintaining similar potency. Most importantly, NC-005 did not
inhibit Casp-L and Tr-L sites at a concentration that caused
nearly complete inhibition of Chym-L sites (0.5 mM, Figure 1C).2009 Elsevier Ltd All rights reserved 1279
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Figure 2. Cytotoxicity of the Novel Proteasome Inhibitor NC-005 Does Not Correlate with the Inhibition of Chym-L Sites
(A) Overall design of experiments. Cells were treated with inhibitors for 1 hr, and then cultured in the absence of the inhibitors for 48 hr, when cell viability was
assayed with an Alamar Blue. At time points indicated, a fraction of cells was harvested (1, 3, 6, 10, and 23 hr) and used for the measurement of apoptosis and of
proteasome peptidase activities.
(B) Recovery of Chym-L activity after 1 hr treatment of RPMI-8226 cells with NC-005. Values are averages ± SE of two experiments. Recovery of Tr-L and Casp-L
activities in RPMI-8226 cells and recovery of all three activities in Dx6 and KMS-18 cells are shown on Figure S1.
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Site-Specific Proteasome InhibitorsAnother difference between YU-101 and NC-005 was that
NC-005 caused stronger activation of Tr-L and Casp-L activities
(50% versus 20%). This activation is most likely allosteric (Kisse-
lev et al., 1999) and is reduced in YU-101 because inhibition of
Casp-L and Tr-L sites occurs at lower concentrations than in
NC-005 treated cells. Another possible explanation for this
effect—increased proteasome activity because of biosynthesis
of new proteasomes—is much less likely because duration of
treatment (1 hr) was too short to activate this transcriptional
response.
NC-005 Is Cytotoxic to Multiple Myeloma Cells, but
Maximal Cytotoxicity Is Achieved at Concentrations
Where It Is No Longer Chymotrypsin-Site Specific
To test whether NC-005 is cytotoxic to multiple myeloma cells,
cells were treated with NC-005 for 1 hr, then incubated in
a drug-free media for 48 hr, followed by measurement of cell
viability with a mitochondrial dye conversion assay (Figure 2A).
Such short treatment was used because it reflects the clinical
situation much better than continuous treatment of cells with
proteasome inhibitors, as usually used in cell culture experi-
ments. Patients are receiving these drugs as an intravenous
bolus injection; within 1 hr after such treatment, proteasome inhi-
bition in blood cells reaches its maximum (i.e., 70% inhibition of
Chym-L activity), but it recovers within the next 24 hr (Hamilton
et al., 2005). Similarly, 1 hr treatment of RPMI-8226 cells with
0.6 mMNC-005 led to 80% inhibition of Chym-L activity, followed
by complete recovery in the next 24 hr (Figure 2B). Recovery was
slower in cells treated with higher concentrations of NC-005. An
additional reason for using 1 hr treatments was that longer incu-
bation led to a slight loss of specificity (data not shown).
Recovery was slower at higher concentrations, and this persis-
tent inhibition of proteasomes resulted in the complete or near-
complete loss of cell viability.
NC-005 was cytotoxic to all myeloma cell lines but sensitivity
variedwidely, with IC50 ranging from 30 nM to 1.5 mM (Figure 2C).
This was unexpected because these cell lines show little differ-
ence in sensitivity to bortezomib (with continuous exposure;
Hideshima et al., 2001). In order to determine whether this differ-
ence is a unique feature of NC-005 or a consequence of short-
ening treatment time to 1 hr, we have treated the same cell lines
with bortezomib for 1 hr. Although the order of sensitivity
changed (i.e., RPMI-8226 was the least NC-005-sensitive cell
line, but Dox6 and KMS-12-BM the least bortezomib-sensitive
lines), similar 50-fold differences in IC50 were observed across
the panel (Figure 2D). Thus, differences in sensitivity in myeloma
cells are a general feature of proteasome inhibitors and not
a unique feature of NC-005. One possible reason for different(C and D) Effect of 1h NC-005 (C) and bortezomib (D) treatment on viability of multi
SE of four to six (C) or two or three (D) experiments.
(E) IC50 (i.e., concentration at which viability was reduced by 50%)was determined
specific activity of Chym-L sites.
(F) Cell viability (fromC andD) was plotted against the inhibition of Chym-L (top pan
(G) Apoptosis of NC-005 treated RPMI-8226 cells. Top panel: Caspase-3 activity is
the cleaved PARP was detected on the western blot (inset). Bottom panel: Percen
Representative results for one out of three different experiments are shown.
(H) Viability of RPMI-8226, Dox6, and KMS-18 cells (as in C) was plotted against t
panel) and 10 hr (bottom panel) after end of 1 hr NC-005-treatment (Figure S1).
Chemistry & Biology 16, 1278–128sensitivity would be that cell lines that are very sensitive to bor-
tezomib and NC-005 express fewer proteasomes. We deter-
mined specific proteasome activity in these cell lines and found
little correlation between this parameter and IC50 for either inhib-
itor (Figure 2E). The reason for this difference is currently being
investigated in the laboratory.
We then asked the question whether inhibiting Chym-L sites
alone is sufficient to induce cytotoxicity in multiple myeloma
cells. In all cell lines, we measured inhibition of all three activities
immediately after the 1 hr treatment (Table 1), when inhibition is
maximal (Figure 2B), and noticed that in the majority of them
maximal cytotoxicity was achieved only at concentrations where
NC-005 coinhibited Tr-L and sometimes Casp-L sites. In order to
test whether cytotoxicity correlates with inhibition of Chym-L
sites, we then plotted (Figure 2F, top panel) cell viability versus
inhibition of these sites (Table 1). Good correlation was observed
only for one cell line, NCI-H929, which was the most sensitive to
NC-005. Some correlation was observed for three others
(MM1.R, MM1.S, and KMS-18). Little or no correlation was
observed for the remaining three lines (RPMI-8226, its doxoru-
bicin-resistant derivative Dox 6, and KMS-12-BM). These data
are in agreement with the recent report of Parlati et al., who found
that specific 80% inhibition of the Chym-L sites causes 70%
reduction in viability of MM1.S cell but only 20%–25% reduction
in viability of HS-Sultan and Molt-4 cells (Parlati et al., 2009). For
the RPMI-8226 and Dox6 cell lines, lack of viability correlated
with inhibition of Tr-L sites (Figure 2F, middle panel). We have
also plotted viability against inhibition of Casp-L sites, but even
in these least-NC-005-sensitive sites viability decreased faster
than activity (Figure 2F, bottom panel). Thus, coinhibition of
Tr-L sites appears to be important for NC-005 cytotoxicity.
A caveat of this analysis is that proteasome activity might
recover, wholly or partially, before apoptosis is induced
(Figure 2B). In that case, average proteasome inhibition between
the end of NC-005 treatment and commitment to apoptosis
would be less than inhibition at 1h, which was used for the corre-
lation analysis presented in Figure 2F. To test whether this is the
case, we have measured apoptosis (Figure 2G) and proteasome
activity during the first 24 hr after treatment (Figure 2B; see
Figure S1 available online). In RPMI-8226 cells, caspase activa-
tion and PARP-cleavage were observed 5 hr after the treatment
(Figure 2G, top panel) and annexin-V-positive apoptotic cells
were detected at 10 hr (bottom panel). Throughout this period,
recovery of proteasome activity at cytotoxic concentrations did
not exceed 30% (Figure 2B; Figure S1). When we plotted cell
viability versus inhibition of Chym-L and Tr-L sites at 5 and
10 hr after the treatment, viability of RPMI-8226 and Dox6 cell
lines again did not correlate with inhibition of Chym-L sites;ple myeloma cells. Mock-treated cells served as control. Values are averages ±
by a four-parameter data fit of dose-response curves (C, D) and plotted against
el) and Tr-L (middle panel) or Casp-L (bottom panel) sites (values from Table 1).
expressed in nmol Ac-DEVD-amc cleaved/min/mg protein, and appearance of
tage of annexin-V-positive apoptotic cells was determined by flow cytometry.
he inhibition of Chym-L (solid lines) and Tr-L (dashed lines) activities at 5 hr (top
9, December 24, 2009 ª2009 Elsevier Ltd All rights reserved 1281
Table 1. Effects of Different Concentrations of NC-005 on Proteasome Activity and Cell Viability
Inhibition of Active Sites (by NC-005 Alone, % Control) Viability (% Control)
Cell line NC-005 (mM) b5 b2 b1 - NC-001 +NC-001
RPMI-8226 0.058 87 ± 2.8 12 ± 9 2 ± 9 103 ± 2 92 ± 3
0.175 98 ± 0.5 7 ± 7 5 ± 2 92 ± 3 67 ± 6
0.52 98 ± 0.3 25 ± 8 20 ± 1 MS 84 ± 7 40 ± 15
1.6 99 ± 0.2 63 ± 5 37 ± 4 38 ± 12 14 ± 4
4.8 99 ± 0.1 88 ± 3 48 ± 2 MC 14 ± 5 7 ± 2
Dox6 0.058 94 ± 0.3 12 ± 4 9 ± 12 101 ± 2 92.5 ± 5
0.175 98 ± 0.0 12 ± 2 17 ± 4 98 ± 5 58 ± 6
0.52 99 ± 0.1 46 ± 2 32 ± 3 MS 55 ± 8 13 ± 6
1.6 99 ± 0.1 78 ± 1 42 ± 4 MC 6.0 ± 3.5 2.5 ± 1.3
KMS-18 0.019 46 ± 8 47 ± 40 4 ± 8 111 ± 9 104 ± 3
0.058 88 ± 3.5 12 ± 10 20 ± 3.5 110 ± 6 80 ± 8
0.175 98 ± 0.2 17 ± 1 17 ± 6 MS 80 ± 6 52 ± 10
0.52 99 ± 0.1 36 ± 6 37 ± 1 20 ± 6 16 ± 8
1.6 99 ± 0.2 64 ± 5 49 ± 5 MC 3.4 ± 0.6 1.6 ± 0.7
MM1.R 0.028 40 ± 2 44 ± 10 80 ± 24 MS 71 ± 8 9 ± 2
0.084 89 ± 1 14 ± 12 45 ± 24 7 ± 3 0.7 ± 0.1
0.252 91 ± 2 4 ± 11 22 ± 13 MC 0.8 ± 0.1 0.7 ± 0.1
MM1.S 0.0064 31 ± 2 0 ± 10 9 ± 3 106 ± 2 99 ± 3
0.019 54 ± 8 13 ± 4 1 ± 8 91 ± 2 73 ± 2
0.058 92 ± 1.5 2 ± 12 14 ± 1 MS 56 ± 6 21 ± 6
0.175 98 ± 0.1 11 ± 9 20 ± 3 15 ± 12 2.2 ± 2
0.52 99 ± 0.1 38 ± 9 36 ± 5 MC 0.65 ± 0.07 0.2 ± 0.0
H929 0.0064 17 ± 2 16 ± 0.5 4 ± 3 97 ± 11 82 ± 9
0.019 45 ± 5 15 ± 20 3 ± 10 MS 79 ± 6 45 ± 10
0.058 87 ± 1 1 ± 21 9 ± 10 22 ± 7 8 ± 5
0.175 97 7 15 MC 8 ± 7 5 ± 4
KMS-12-BM 0.019 83 0 8 112 ± 9 n.t.
0.058 97 ± 0 11 ± 2 17 ± 2 72 ± 21 n.t.
0.17 98 ± 0 21 ± 8 19 ± 9 31 ± 5 n.t.
0.52 99 ± 0 50 ± 5 35 ± 0.4 14 ± 4 n.t.
1.6 100 ± 0 83 ± 3 48 ± 4 MC 2.4 ± 0.1 n.t.
4.8 100 ± 0 92 ± 0.4 58 ± 4 1.2 ± 0.3 n.t.
PBMNC 0.019 63 ± 3 0 ± 3 3 ± 5 96 ± 7 90 ± 10
0.058 92 ± 3 0 ± 7 15 ± 1 MS 77 ± 2 39 ± 1
0.175 98 ± 1 21 ± 12 9 ± 3 43 ± 1 22 ± 1
0.52 99 ± 1 59 ± 18 9 ± 7 15 ± 1 7 ± 0
1.6 100 ± 2 97 ± 6 42 ± 13 MC 4 ± 0.3 3.5 ± 0.4
MDA-MB-231 0.009 39 ± 14 20 ± 32 25 ± 30 99 ± 4 100 ± 9
0.028 81 ± 8 33 ± 48 43 ± 48 101 ± 0 84 ± 3
0.084 95 ± 6 12 ± 18 26 ± 14 MS 85 ± 4 33 ± 6
0.252 96 ± 3 8 ± 18 42 ± 23 39 ± 6 7 ± 1
0.756 99 ± 3 59 ± 2 9 ± 4 MC 6 ± 1 5 ± 1
Cells were treated with NC-005 for 1 hr, followed by themeasurement of proteasome peptidase activities; another fraction of NC-005-treated cells was
cultured for 48 hr in the presence or absence of 2 mM NC-001 (10 mM in case of Dox-6 cells), after which cell viability was measured with Alamar Blue
assay. Viability data is the same as on Figure S3. MS-maximal sensitization by NC-001; MC-maximal cytotoxicity (NC-005 alone); n.t., not tested.
Values are averages ± SE of two or three (inhibition) or two to five (viability) independent measurements.
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Figure 3. NC-005-Derived Active-Site Probe and Its Inactive Diaste-
reomer Demonstrate that NC-005 Is Proteasome Specific
(A) RPMI-8226 cells were treated with az-NC-005 active-site probe. Activities
were measured (values are averages ± SE of two experiments) and, in parallel,
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Chemistry & Biology 16, 1278–128much better correlation was observed between viability and inhi-
bition of Tr-L sites (Figure 2H). Thus, coinhibition of Tr-L sites
contributes to the cytotoxic effects of NC-005.
Another explanation for the lack of correlation between inhibi-
tion of Chym-L sites and cytotoxicity would be an off-target
effect of NC-005. Although we considered such scenario as
unlikely because of specificity of epoxyketones, we decided to
use the chemical tools at our disposal to demonstrate that NC-
005 does not, in fact, interact with other cellular proteins. We
therefore converted it into an active site probe (i.e., irreversible
inhibitor with a reporter group attached to it). We have used
a two-step labeling strategy, which we successfully applied in
our previous studies (van Swieten et al., 2007), in which a small
azido group is added to the molecule of interest. After the probe
irreversibly attaches to its targets inside cells, cell extracts are
prepared and treated with azido-reactive biotinylated phos-
phane. The phosphane reacts selectively with azide in a Stau-
dinger-Bertozzi ligation, resulting in the biotinylation of the inhib-
itor targets. Biotinylated polypeptides can be then visualized on
western blots or isolated by affinity chromatography and identi-
fied by mass spectrometry. The advantage of this two-step
strategy is that an azide normally does not alter cell permeability
or active-site specificity of the compound. Contrary to this, direct
synthetic incorporation of biotin or a fluorescent moiety, which is
required for a one-step labeling procedure, often alters active-
site specificity and decreases cell permeability.
When phosphane-treated extracts of az-NC-005-treated
RPMI-8226 cells were separated on SDS-PAGE, a well-charac-
terized pattern of bands of proteasomes active subunits (Altun
et al., 2005) was detected. Labeling was concentration depen-
dent, with the b5/b5i band appearing first, followed by b2i, b2,
b1, and b1i bands. Other bands were background bands from
nonspecific reaction of phosphane with cellular proteins and
a band of endogenously biotinylated protein of 70 kDa (which
can serve as a loading control). Appearance of proteasome
subunit bands generally correlated with the inhibition of the cor-
responding activities (Figure 3A). One notable exception was
that the b2i band was detected on the gel at 0.3 mM az-NC-
005, when Tr-L activity was still at 100%. However, it should
be noted that maximal Tr-L activity in this experiment is 140%.
Thus, az-NC-005 and, presumably, NC-005 itself do not have
an off-target effect due to irreversible modification of nonprotea-
somal targets.
These experiments with az-NC-005 did not exclude the possi-
bility that some of NC-005’s effects are due to noncovalent
binding to other cellular proteins. In order to rule out this possi-
bility, we inverted the stereochemistry of the Ca atom of the
epoxy-ring from (R) to (S) configuration, producing a compoundextracts of these cells were treated with biotinylated phosphane (Figure 4G)
and analyzed by western blotting. Az-NC-005-reacting polypeptides were
visualized by staining with fluorescently labeled Streptavidin and identified
based on the well-characterized pattern of migration of proteasome’s catalytic
subunits (Altun et al., 2005). Endogeneously biotinylated protein of 70 kDa
served as a loading control.
(B) RPMI-8226 cells were treated with 1.6 mMNC-005 and (S)-NC-005 for 6 hr.
Proteasome activities were measured immediately after the treatment using
peptides substrates (table); cell viability was measured after subsequent
42 hr cultivation in inhibitor-free media.
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Figure 4. NC-001 Is a Highly Specific, Cell-
Permeable Inhibitor of Casp-L Sites
(A) Structures of NC-001, NC-001-derived probe
and its inactive diastereomers.
(B-D) Casp-L (B) and Chym-L and Tr-L activities
(C) of the proteasome during continuous treat-
ment of cells with NC-001. Panel D shows all three
activities 6 hr after treatment.
(E) Proteasome peptidase activities in cells treated
with az-NC-001 for 6 hr.
(F) Casp-L activity of the proteasome in cells
treated for 6 hr with az-NC-005 diastereomers.
All activity measurements were performed in
RPMI-8226 cells and are averages ± SE of two
independent experiments, in which mock-treated
cells served as control.
(G) Extracts of these cells (i.e., from experiment
shown in E and F) were treated with biotinylated
phosphane (BioP), separated on 12% gel, trans-
ferred on PVDF membrane, and probed with fluo-
rescently labeled Streptavidin. Polypeptides
modified by the probes were identified by incu-
bating the membrane with fluorescently labeled
Streptavidin. Extracts treated with biotinylated
non-site-specific inhibitor Ada-Bio-Ahx3-Leu3-VS
were used to identify the migration pattern of pro-
teasome bands (Altun et al., 2005). Endogene-
ously biotinylated protein of 70 kDa can be
used as a loading control.
(H) Isolation of az-NC-001-modified subunits by
Streptavidin affinity chromatography. Extracts of
cells treated overnight with 5 mM az-NC-001 or
mock-treated were treated with BioP, passed
through a Streptavidin-Sepharose HP column (to
remove excess BioP), treated with SDS (to disso-
ciate proteasome subunits), and re-incubatedwith
Streptavidin-Sepharose. After extensive washing
of the beads, specifically bound proteins were
eluted with 1 mM biotin in LDS gel loading buffer
at 95C, fractionated on SDS-PAGE, and analyzed
by western blotting with antibodies to proteasome
subunits indicated. Percentage of total sample
loaded on the gels are indicated. Figure S2
demonstrates that modification with az-NC-001
and BioP results in the mobility shift of the b1
subunit.
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used at the same concentration as the concentration of NC-
005 that caused 93% reduction of cell viability, (S)-NC-005
was not cytotoxic to RPMI-8226 cells (Figure 3B). Thus, cytotox-
icity of NC-005 is dependent on its ability to covalently modify
proteasome active sites. This lack of off-target effects of NC-
005 supports the view that a need to coinhibit Tr-L sites is amajor
reason for the lack of correlation between inhibition of Chym-L
sites and cytotoxicity.
Development of Potent, Specific, Cell-Permeable
Inhibitor and Active-Site Probe of Caspase-like Sites
That inhibition of Chym-L sites is often insufficient to achieve
maximal cytotoxicity suggests that inhibitors of Casp-L and
Tr-L sites should enhance the cytotoxic effect of the inhibitor
of Chym-L sites. Building on our expertise in the development
of highly specific peptide aldehydes and peptide vinyl sulfone1284 Chemistry & Biology 16, 1278–1289, December 24, 2009 ª2009inhibitors of Casp-L (b1i and b1) sites (Kisselev et al., 2003;
van Swieten et al., 2007), we have synthesized an epoxyketone
analog of these compounds, Ac-APnLL-ek, which we designate
NC-001 (Figure 4A).
Treatment of cells with NC-001 results in a specific, time- and
concentration-dependent inhibition of b1 sites (Figure 4B).
Maximal (close to 100%) inhibition was achieved upon 5 hr treat-
ment with 2 mM inhibitor. The IC50 of the inhibitor after 6 hr treat-
ment was 0.5 mM. Longer treatment (up to 24 hr) with NC-001
slightly improved inhibition at lower concentration (Figure 4B)
without any loss of specificity, even at 4 mM (Figure 4C). Thus,
NC-001 is a potent, cell-permeable, and highly specific inhibitor
of Casp-L sites. NC-001 specifically inhibited Casp-L sites in all
cell lines tested (data not shown).
To confirm that NC-001 does not have any off-target effects
and to compare its specificity toward Casp-L sites of constitutive
and immunoproteasomes (b1 and b1i sites), we converted it intoElsevier Ltd All rights reserved
NC-001 (µM) :  
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MM1.R+NC-005 (nM)+/-NC-001:
          (2)39 (25-53)38 (24-52)KMS-12-BM
0.012 (3)188 (98-282)298 (220-376)KMS-18
0.019 (3)211 (155-267)573 (429-717)Dox-6
0.028 (4)399 (169-269)1357 (645-2069)RPMI-8226
0.15 (2)32 (26-38)70 (46-94)MM1.S
0.00085 (5)25 (17-33)50 (36-64)MM1.R
0.0025 (6)17 (15-21)34 (26-42)NCI-H929
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+NC-001No NC-001
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Figure 5. NC-001 Sensitizes Cells to NC-005
(A and B) RPMI-8226 cells were treated with
NC-005 for 1 hr and then split into two equal
portions. One was treated with NC-001 (at con-
centrations indicated, A), or az-NC-001, or az-(S)-
NC-001 (B) and the other was mock-treated for
48 hr, when cell viability was measured with Ala-
mar Blue. Values are averages ± SE of two inde-
pendent experiments.
(C) NC-001 reduces IC50 of NC-005 (i.e., concen-
tration at which cell viability is reduced by one-
half compared with mock-treated cells) in multiple
cell lines. IC50 for each individual experiment (per-
formed as in A) were determined by a four-param-
eter fit of dose-response curves (Figures S3A
[RPMI-8226 cells], 5D [MM1.R cells], and S3B [all
other cell lines]). Values in the table are averages
(confidence intervals). Results of the t test are
provided in the last column (p value; n, number of
times experiment was repeated). NC-001 was
used at 2 mM except in Dox 6 cells where it was at
10 mM.
(D and E) NC-001 (2 mM) sensitizes MM1.R cells to
NC-005 by reducing IC50 (D) and accelerating cell
death. Experiment in (E) was performed as in (A),
except that at different time points aliquots of cells
were collected and analyzed for apoptosis using
Annexin V staining (E). Values are averages ± SE
of two or three experiments. Figure S3A demon-
strates that sensitization of cells to NC-005 by
NC-001 does not depend on the order of treatment
with these reagents. Figure S3B demonstrates
sensitization of other myeloma cells lines to
NC-005 by NC-001.
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the same strategy as for synthesis of NC-005 derivatives, we
have generated an NC-001 derivative carrying an azido-group
(az-NC-001) and an az-(S)-NC-001 diastereomer with the in-
verted configuration of the Ca atom of the epoxygroup
(Figure 4A). In addition, we have purified and isolated az-D-
NC-001, a compound with D-Nle in the P2 position, which is
generated as a byproduct at the last step of the synthesis.
Az-NC-001 specifically inhibited Casp-L sites in RPMI-8226
cells (Figures 4D and 4E). Treatment of extracts of az-NC-001-
treated cells with biotinylated phosphane revealed dose-depen-
dent labeling of b1 and b1i subunits (Figure 4G). We could not
detect any other modified polypeptide. Proteasome-specific
labeling was substantially reduced in az-(S)-NC-001 and az-D-
NC-001 (Figure 4G), which were also much less potent in inhibit-
ing Casp-L activity (Figure 4F). In order to confirm that all signal
in the b1 and b1i bands indeed comes from b1 and b1i subunits
and not from nonresolved b5 and b5i subunits, we denatured
proteasomes in extracts of cells treated with high concentrations
(5 mM) of az-NC-001and isolated individual subunits on Strepta-
vidin-Sepharose beads (Figure 4H). b1 and b1i subunits were
abundantly detected in the eluates; no b5 and only traceChemistry & Biology 16, 1278–1289, December 24, 2009 ªamounts b5i were detected eluted from
these columns. This analysis also re-
vealed that b1 and b1i band shifts upward
slightly upon modification of the probe(see also Figure S2). Thus, az-NC-001 is a specific probe for
Casp-L sites of constitutive proteasomes and immunoprotea-
somes.
NC-001 Sensitizes Cells to NC-005
Treatment of cells with NC-001 alone did not cause any growth
inhibition or cytotoxicity. This is in agreement with yeast data,
where inactivation of this site by mutation caused no phenotypic
defect (Arendt andHochstrasser, 1997; Heinemeyer et al., 1997).
We next set out to determine whether inhibiting Casp-L sites
increases the cytotoxic effects of Chym-L sites inhibitors. In
the initial experiment, we treated RPMI-8226 cell lines with
different concentrations of NC-005 for 1 hr and then with
different concentrations of NC-001 for 48 hr, whereupon cell
viability was measured with the Alamar Blue mitochondrial dye
conversion assay (Figure 5A). High concentration of NC-001
(1–4 mM) sensitized cells to NC-005, leading to up to 5-fold
decrease in IC50 (Figure 5A). These concentrations inhibit
Casp-L sites bymore than 90% (Figure 4D). Lower concentration
of NC-001 (<0.5 mM), which caused less than 80% inhibition of
Casp-L sites, did not sensitize RPMI-8226 cells to NC-005. Inac-
tive NC-001 analog, az-(S)-NC-001, did not sensitize RPMI-82262009 Elsevier Ltd All rights reserved 1285
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Site-Specific Proteasome Inhibitorscells to NC-005 (Figure 5B). Thus, sensitization of cells to inhib-
itors of Chym-L sites is due to the inhibition of Casp-L sites.
We then tested whether sensitization is affected by the order
of inhibitors in treatment (Figure S2). In the first experiment, cells
were treated with NC-005 for 1 hr and then by 2 mM NC-001 for
48 hr. In the second experiment, cells were cotreated with
NC-005 and 18 mM NC-001 for 1 hr. (One hour incubation with
18 mM NC-001 caused similar inhibition of Casp-L sites as
6–24 hr treatment with 2 mM compound). In the third experiment,
RPMI-8226 cells were pretreated with 2 mMNC-001 for 6 hr, then
treated with NC-005 for 1 hr. Similar sensitization was observed
under these different conditions. We then decided to use 1 hr
treatment with NC-005 followed by continuous treatment with
NC-001, as this allowed a simpler experimental set-up than
1 hr cotreatment or pretreatment with NC-001 and allowed us
to keep NC-001 concentrations as low as possible. Duration of
NC-005 was limited to 1 hr for the same reasons as in initial
experiments (Figure 2).
We then tested the effect of NC-005 and NC-001 on other
multiple myeloma cell lines (Figures S3B, 5C, and Table 1). In
these experiments, we used only one concentration of NC-
001, namely that caused 90%–99% inhibition of Casp-L activity
(10 mM inDox-6 cells, 2 mM in all others). NC-001 sensitized other
multiple myeloma cell lines to NC-005, causing a 2–3.5-fold
decrease in IC50 (Figure 5C). This group contained the majority
of cell lines where inhibition of Chym-L sites was insufficient to
achieve maximal cytotoxicity (Table 1) but also included the
MM1.R (Figure 5D) and NCI-H929 and cell lines, where inhibition
of Chym-L sites alone was strongly cytotoxic (Table 1). NC-001
also sensitized MDA-MB-231 breast cancer cell lines and
peripheral blood mononuclear cells (PBMNCs, Figure S3B).
Although this sensitization effect was not observed at high and
low concentrations of NC-005, at concentrations close to IC50
for viability, NC-001 caused a 30%–50%decrease in cell viability
in all cell lines (Table 1). Thus, the inhibitor of Casp-L sites
NC-001 sensitizes cells to inhibitors of Chym-L sites.
In addition to the end-point increase of cytotoxicity, NC-001
increased the rate of NC-005–induced cell death. For example,
in MM1.R cells treated with 30 nM NC-005, the rate of apoptosis
was doubled in the presence of NC-001 (Figure 5E). Similar
results were obtained in RPMI-8226 cells (data not shown).
Thus, the inhibition of Casp-L sites not only increases the
number of cells that undergo cell death in response to the inhibi-
tion of Chym-L sites but also enhances the rate of this process.
Is sensitization of cells to the inhibitor of Chym-L sites by
NC-001 clinically significant? To be so, sensitization should be
observed upon inhibition of b5 sites at levels that are clinically
achievable. At the maximal tolerated dose, bortezomib causes
80% inhibition of Chym-L activity of the proteasome in blood
(Hamilton et al., 2005); newer agents can achieve 90% inhibition
(Demo et al., 2007). We have used measurements of inhibition of
all three active sites in NC-005-treated cells (Table 1) to deter-
mine the extent of Chym-L sites inhibition needed for sensitiza-
tion by NC-001. In NCI-H929 and MM1.R cells, sensitization
was observed upon 40%–60% inhibition of Chym-L activity,
and thus is clinically relevant (Table 1). In other myeloma cells,
maximal sensitization occurred upon 90%–99% inhibition of
Chym-L sites (Table 1). This exceeds in vivo inhibition achievable
by bortezomib, but can be achieved by three new agents, carfil-1286 Chemistry & Biology 16, 1278–1289, December 24, 2009 ª2009zomib, salinosporamide A, and CEP-18770 (Chauhan et al.,
2005; Demo et al., 2007; Piva et al., 2008), which are undergoing
clinical trials. Thus, sensitization of MM1.R cells by NC-001 is of
potential clinical significance.
Another interesting question is whether NC-001 treatment
alters recovery of Chym-L and Tr-L activities in NC-005-treated
cells. In MM1.R (Figure 6A) and NCI-H929 cells (Figure S4A),
NC-001 treatment did not change inhibition of the chymotrypsin-
and Tr-L sites. In RPMI-8226 (Figure 6B) and Dox 6 (Figure S4A)
cells, NC-001 reduced the recovery of Chym-L activity.
However, the effect was small during first 11 hr and became
significant only at 24 hr, long after apoptosis has been triggered
(Figure 2G). It was most pronounced at 175 nM, was smaller at
520 nM, and at 1.6 mM there was no effect. Thus, it occurred
only at concentrations that cause partial loss of viability
(Figure 5A), suggesting that recovery occurs only in the cells
that do not undergo apoptosis; these still have functional protein
biosynthesis machinery and can synthesize new proteasomes.
NC-001 reduces this fraction and thus decreases recovery.
NC-005–treated MM1.R and H929 cells die at faster rates
(compare rate of RPMI-8226 cell death on Figure 2G and of
MM1.R cell death on Figure 5E), and activity does not get
a chance to recover.
DISCUSSION
Earlier studies have firmly established Chym-L sites of protea-
somes as targets of antineoplastic agents (Adams, 2004). The
Casp-L and Tr-L sites were not initially considered as such,
but recent studies have suggested that the ability to cotarget
them can be important for the antineoplastic activity of protea-
some inhibitors (Altun et al., 2005; Berkers et al., 2005;
Chauhan et al., 2005) and for their ability to inhibit protein
breakdown (Kisselev et al., 2006). Lack of highly specific,
cell-permeable active-site inhibitors has prevented investiga-
tors from directly testing this hypothesis. In this study, we
describe the development of such inhibitors and provide direct
evidence that Casp-L sites have to be considered cotargets of
proteasome inhibitors alongside with Chym-L sites. These
data also strongly suggest that cotargeting Tr-L sites could
be at least as important as cotargeting Casp-L sites.
First, cytotoxicity of NC-005 to several multiple myeloma cell
lines correlates poorly with the inhibition of Chym-L sites (Figures
2F, 2H). Second, in themajority of cell lines tested,maximal cyto-
toxicity is achieved only when Tr-L sites are coinhibited (Table 1).
Third, the specific inhibitor of Casp-L sites, although noncyto-
toxic to these cell lines when used as a single agent, sensitizes
cells to NC-005 (Figure 5; Figure S3).
The conclusion that Chym-L sites are the primary targets of
antineoplastic agents was based on earlier reports in which
panels of different peptide boronates (Adams et al., 1999) or
peptide epoxyketones (Elofsson et al., 1999) were tested for
ability to inhibit cell growth. This ability correlated with their
capacity to inhibit Chym-L sites in vitro assays of the purified
proteasomes. The extent of inhibition of these sites inside cells
and whether Casp-L and Tr-L site were also inhibited at cyto-
toxic and growth-inhibitory concentrations was not tested.
These differences in the experimental design between those
studies and our work are the most likely reasons for our differingElsevier Ltd All rights reserved
A MM1.R cells B RPMI-8226 cells
(2 µM)
(2 µM)
Figure 6. Effect of NC-001 on Recovery of
Proteasome Activity in NC-005-Treated
Cells
(A) MM1.R cells were treated with NC-001 in the
presence or absence of 2 mM NC-001 for 1 hr, fol-
lowed by incubation in media in the presence or
absence of NC-001 respectively. At times indi-
cated, some cells were harvested and protea-
some activity was measured in extracts with fluo-
rogenic peptide substrates and normalized permg
total protein (determined by Bradford). No inhibi-
tion of Tr-L activity was observed.
(B) RPMI-8226 cells were treated with NC-005 for
1h, followed by the NC-001 or mock-treatment. At
times indicated proteasome activity was mea-
sured with ProteasomeGlo assay and normalized
per number cell at time zero. Time-dependent
decrease in Tr-L and Casp-L activity in RPMI-
8226 cells treated with higher concentrations of
NC-005 reflects time-dependent decrease in the
number of cells due to inhibition of cell prolifera-
tion or cell death. Solid lines, no NC-001; dashed
lines, with NC-001. Values are averages ± SE of
two independent experiments. Figure S4A
demonstrates effects of NC-001 on recovery of
proteasome activity in NC-005 treated Dox6 and
KMS-18 cells. Figure S4B demonstrates that Pro-
teasomeGlo and fluorogenic substrate assays
give identical results.
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achieved without inhibition of Chym-L sites, was reported by
two studies claiming that inhibition of b1i sites (i.e., Casp-L sites
of immunoproteasomes) is sufficient to induce apoptosis in cells
that express high amounts of immunoproteasomes (Ho et al.,
2007; Kuhn et al., 2009). This is in a disagreement with the
present work, because we demonstrate that complete inhibition
of both b1 and b1i sites did not cause any growth inhibition or
cytotoxicity in any of the cell lines tested. Possible reasons for
this difference are (a) that effects of b1i-specific inhibitors are
cell-line specific, or (b) that b1i inhibitors are not as specific as
NC-001 and coinhibit Chym-L activity (b5i) at cytotoxic concen-
trations.
What are the implications of these results for the development
of therapeutic proteasome inhibitors? The first significant obser-
vation of this study is that at clinically achievable 70% inhibition
of Chym-L sites (Hamilton et al., 2005), cytotoxicity is achieved
only in a fraction of cell lines tested, and even in these, stronger
inhibition is needed to achieve maximal cytotoxicity (Figure 2F,
Table 1). Similar results were observed with bortezomibChemistry & Biology 16, 1278–1289, December 24, 2009 ª(Figure 2D andmanuscript in preparation)
and carfilzomib (Parlati et al., 2009).
These results suggest that insufficient
proteasome inhibition is the main reason
why only a fraction of patients respond
to bortezomib as a single agent (Richard-
son et al., 2003). Based on this data, we
predict that the next generation of pro-
teasome inhibitors (e.g., carfilzomib,
NPI-0052, and CEP-18770) that can
achieve stronger (90%–95%) in vivo inhi-bition of Chym-L activity (Chauhan et al., 2005; Demo et al.,
2007; Piva et al., 2008), will be more potent antineoplastic
agents. Early results of phase II trials of carfilzomib confirm this
prediction, because this agent is able to achieve responses in
bortezomib-refractory myeloma patients (Jagannath et al.,
2008).
Our data clearly indicate that coinhibiting Chym-L and Casp-L
sites should lead to a more potent antineoplastic agent and
strongly suggest that coinhibiting Tr-L sites should have similar
effect. Of particular importance is that, in at least two cell lines,
sensitization by NC-001 occurs upon clinically achievable
(<70%) inhibition of Chym-L sites. In a number of other cell lines,
stronger inhibition was needed to achieve this sensitization.
Such stronger inhibition can be achieved in vivo by the second
generation of proteasome inhibitors. However, if this leads to
a higher toxicity to normal cells (as our data in PBMNCs indicate),
the clinical usefulness of this phenomenon may be limited, and
in vivo experiments are needed to address this issue. Poor solu-
bility of NC-001 and NC-005 has prevented us from performing
these experiments, which will be done after analogs of these2009 Elsevier Ltd All rights reserved 1287
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developed.
Allosteric interactions between active sites observed in these
and earlier studies (i.e., activation of Casp-L and Tr-L activities
upon occupancy of Chym-L sites by inhibitors, activation of
Tr-L sites by inhibitors of Casp-L sites, cooperativity between
Chym-L sites [Kisselev et al., 1999]) may further contribute to
inhibitor resistance, because inactivation of one site by an inhib-
itors would automatically lead to other sites cleaving proteins at
faster rates. Thus, allostericity may also be one of the mecha-
nisms behind sensitizing effects, as inhibiting the second site
may take away the benefits of the allosteric activation upon inhi-
bition of the first site.
The importance of our work goes beyond treating cancer. The
proteasome is involved in the regulation of a variety of cellular
processes, and this work will inevitably raise questions about
the roles of individual active sites in these processes. The most
interesting application of compounds developed in this study
would be to investigate the role of individual active sites in
antigen presentation (Groettrup and Schmidtke, 1999). The
fact that all three types of site are different in immunoprotea-
somes strongly suggests that they are important in this process.
Even if an active site (e.g., Casp-L) is of little importance to over-
all protein degradation, its activity may be critical for the precise
excision of certain epitopes. Specific inhibitors of this site would
block presentation of this epitope. Conversely, some epitopes
may be destroyed by the specific action of an active site, and
their presentation would be enhanced by its specific inhibitor.
Site-specific inhibitors, active-site probes, and their inactive
analogs developed in these studies, and specific cell-permeable
inhibitors of Tr-L sites we are currently developing, will allow us
to test this hypothesis in future work.SIGNIFICANCE
This study provides the first direct evidence that Casp-L pro-
teasome sites must be considered cotargets of antineo-
plastic drugs (along with Chym-L sites) and strongly suggest
that cotargeting of Tr-L sites would increase antineoplastic
activity of proteasome inhibitors. The highly specific, potent,
and cell-permeable inhibitors of Casp-L and Chym-L sites
described here would be excellent tools to study the role
of these active sites in a variety of biological processes
(e.g., antigen presentation). Used together, these inhibitors
would enable study of the effect of combined inhibition in
which inhibition of each site is varied to any desired extent
(e.g., 50% inhibition of Chym-L sites and 95% inhibition of
Casp-L sites), which cannot be achieved by any of the
currently available compounds. The active-site probes and
inactive analogs described here would provide a unique
capability to infer that observed biological effects are indeed
due to inhibition of the proteasome’s active sites.EXPERIMENTAL PROCEDURES
Materials
26S proteasome was purified from rabbit muscle as described previously
(Kisselev et al., 2002), except that 1 hr centrifugation of extract at 100,000 g
was replaced by a 30 min centrifugation at 40,000 g. YU-101 was purchased1288 Chemistry & Biology 16, 1278–1289, December 24, 2009 ª2009from Calbiochem, bortezomib was purchased from DHMC pharmacy.
MV-151, AdaBio-Axh3-Leu3-VS, and biotinylated phosphane were synthe-
sized as described elsewhere (van Swieten et al., 2007). Synthesis of
NC-001, NC-005, az-NC-001, az-D-NC-001, and az-(S)-NC-001, az-NC-005,
and (S)-NC-005 is described in the Supplemental Data section, which also
contains analytical data for these inhibitors. Stock solutions of inhibitors
were prepared in dimethyl sulfoxide and their concentrations were determined
by amino acid analysis.
Measurements of proteasome activity in cells extracts were performed as
described by Kisselev andGoldberg (2005). Suc-LLVY-7-amido-4-methylcou-
marine (amc, Bachem), Ac-nLPnLD-amc, and Ac-RQR-amc (both custom
synthesized by MP Biomedicals) were used for the measurements of Chym-L,
Casp-L, and Tr-L activities, respectively. Proteasome activity in cells was
measured using Promega ProteasomeGlo Cell-Based Assay (Promega)
(Moravec et al., 2009). Results of cell- and extracts-based assays were indis-
tinguishable (Figure S4B). See Supplemental Experimental Procedures for
details of both procedures.
The Experimental Procedures section of the Supplemental Data contains
detailed information on following procedures: visualization of polypeptides
modified by the subunit-specific active site probes in a two-step procedure,
isolation of modified subunits on Streptavidin-Sepharose, apoptosis, and
cell viability assay.SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and four
figures and can be found with this article online at http://www.cell.com/
chemistry-biology/supplemental/S1074-5521(09)00407-4.ACKNOWLEDGMENTS
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